Sequentia Biotech announces a €10million Series A, led by Seventure Partners, a French Venture Capital & Growth investment company with an extensive experience in Life Sciences. The Series A is co-invested by the EIC Fund, the European Commission initiative dedicated to accelerating innovative start-ups across the European Union. Across Legal advised Sequentia Biotech on this deal with a team comprised of Ignacio Lacasa, Marc Pereta, Víctor Martín Ratia, Borja Vallejo, and Daniele Matías Moro Valls.
The investment will accelerate Sequentia Biotech’s mission to drive innovation in the field of omics (the collective characterization and quantification of pools of biological molecules that translate into the structure function and dynamics of an organisms). Examples of omics include genomics, transcriptomics, epigenomics and microbiomics. The application of omics is driving the development of more precise diagnostic tools in the fields of biomedicine, agritech (e.g. crop protection and nutrition) and in the food industry (e.g. improving food production and quality).
The funds will enable Sequentia Biotech to accelerate the market introduction and expansion of its flagship platform, MICK, and the scale up of its Best-in-Class Bioinformatics Enabling Technologies, driving its ambitious go-to-market strategy.
Walter Sanseverino, CEO and Co-Founder at Sequentia Biotech, welcomed the funding stating, “We are delighted to announce this fundraising and our backing by Seventure Partners and the EIC Fund, two highly renowned venture capital investors with strong track records in supporting innovative companies in the life sciences sector.
